Candel Therapeutics

Company

Related News

Pfizer Secures FDA Approvals for Two Cancer Drugs; Oncolytic Virus Pipeline Expands

Jun 01, 2026

The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.

Candel Therapeutics Secures $100M Royalty Funding from RTW for Prostate Cancer Therapy

Feb 20, 2026

Candel Therapeutics announced a $100 million royalty funding agreement with RTW Investments, contingent on FDA approval of aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, with tiered royalties on U.S. net sales.